- Patent Title: Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
-
Application No.: US15712247Application Date: 2017-09-22
-
Publication No.: US11028151B2Publication Date: 2021-06-08
- Inventor: Erik Depla , Catelijne Stortelers , Stephanie Staelens
- Applicant: Ablynx N.V.
- Applicant Address: BE Ghent-Zwijnaarde
- Assignee: Ablynx N.V.
- Current Assignee: Ablynx N.V.
- Current Assignee Address: BE Ghent-Zwijnaarde
- Agency: Wolf, Greenfield & Sacks, P.C.
- Main IPC: C07K16/10
- IPC: C07K16/10 ; A61M11/00 ; A61M15/00 ; A61K39/00
Abstract:
Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV.
The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
Public/Granted literature
Information query
